COCP · Cocrystal Pharma, Inc.

Cocrystal Pharma reported first-quarter FY2026 results reflecting its clinical-stage antiviral focus, with grant revenue of $225K from an NIH SBIR award providing initial income recognition. This revenue generated an operating margin of -1047.1%, underscoring the pre-revenue nature of operations where no products are approved for sale and ongoing losses persist since inception.

Operating income was -$2.4M, a -64.1% YoY worsening from -$2.3M, as reductions in Influenza A Phase 2a clinical trial expenses were counterbalanced by G&A increases of $229K. This uptick stemmed predominantly from elevated legal and consultant costs tied to a dispute with the CRO, prompting a demand letter and arbitration initiation to enforce agreement terms. Such dynamics highlight R&D cost stabilization post-trial wind-down but expose vulnerabilities from external disputes that could delay programs and inflate overhead.

Net income narrowed slightly by 8.7% to -$2.3M from the prior-year -$2.3M level, improving diluted EPS 26.1% to -$0.17 from -$0.23. This per-share gain reflects stable share count amid persistent losses, with profitability hinging on successful product candidate development, regulatory approval, and revenue generation to match the cost structure.

Cash flows from operations used -$2.3M, a moderation from -$2.9M YoY, driven by lower Influenza trial-related expenses. These negative cash flows, consistent since inception, emphasize the absence of sustainable revenue to cover costs. Management's going-concern basis assumes asset realization and liability settlement in normal business, but continued capital raises remain essential until profitability.

The CRO arbitration introduces program risks, as flawed Phase 2a execution threatens Influenza antiviral advancement and incurs additional costs. With no established revenue source, these factors amplify liquidity pressures, reinforcing the need for funding to sustain operations and pursue commercialization milestones.